Immuneering Corporation (IMRX)

NASDAQ: IMRX · IEX Real-Time Price · USD
10.13
-0.24 (-2.31%)
At close: Mar 27, 2023, 4:00 PM
10.33
+0.20 (1.97%)
After-hours: Mar 27, 2023, 6:51 PM EDT

Stock Price Forecast

According to 13 stock analysts, the average 12-month stock price forecast for Immuneering stock is $16.32, which predicts an increase of 61.11%. The lowest target is $5.05 and the highest is $26.25. On average, analysts rate Immuneering stock as a buy.
Analyst Consensus: Buy
Target Low Average Median High
Price $5.05 $16.32 $16.32 $26.25
Change -50.15% +61.11% +61.11% +159.13%

Analyst Ratings

The average analyst rating for Immuneering stock from 13 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating Oct '22Nov '22Dec '22Jan '23Feb '23Mar '23
Strong Buy 555555
Buy 666666
Hold 222221
Sell 000001
Strong Sell 000000
Total 131313131313

Financial Forecast

Revenue This Year
174.86K
from 316.95K
Decreased by -44.83%
Revenue Next Year
573.75K
from 174.86K
Increased by 228.12%
EPS This Year
-2.57
from -1.91
EPS Next Year
-2.77
from -2.57
Year 201920202021202220232024202520262027
Revenue
1.92M2.31M2.08M316.95K174.86K573.75K16.08M72.98M193.68M
Revenue Growth
-
20.41%
-10.02%
-84.76%
-44.83%
228.12%
2,702.44%
353.87%
165.40%
EPS
-2.18-3.44-2.46-1.91-2.57-2.77-3.03-1.72-0.62
EPS Growth
---------
No. Analysts ----97544

Revenue Forecast

Revenue 20232024202520262027
High 1.1M 1.3M 56.1M 225.0M 398.3M
Avg 174,859 573,750 16.1M 73.0M 193.7M
Low n/a n/a n/a n/a 392,000

Revenue Growth

Revenue Growth 20232024202520262027
High
231.3%
620.6%
9,682.8%
1,299.0%
445.8%
Avg
-44.8%
228.1%
2,702.4%
353.9%
165.4%
Low - - - -
-99.5%

EPS Forecast

EPS 20232024202520262027
High -2.31 -1.95 -2.34 0.17 2.56
Avg -2.57 -2.77 -3.03 -1.72 -0.62
Low -2.80 -3.09 -3.53 -3.47 -3.58

EPS Growth

EPS Growth 20232024202520262027
High - - - - -
Avg - - - - -
Low - - - - -
Sources: Price target, rating and forecast data provided by Finnhub and sourced from Wall Street analysts and other sell-side and buy-side analysts and investors. Data disclaimer.